Literature DB >> 8675297

Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis.

M A Jagels1, J Travis, J Potempa, R Pike, T E Hugli.   

Abstract

The anaerobic bacterium Porphyromonas gingivalis has been implicated as a primary causative agent in adult periodontitis. Several proteinases are produced by this bacterium, and it is suggested that they contribute to virulence and to local tissue injury resulting from infection by P. gingivalis. Cysteine proteinases with specificities to cleave either Arg-X or Lys-X peptide bonds (i.e., gingipains) have been characterized as predominant enzymes associated with vesicles shed from the surface of this bacterium. It has recently been demonstrated that these proteinases are capable of degrading the blood complement component C5, resulting in the generation of biologically active C5a. By using an affinity-purified rabbit antibody raised against residues 9 to 29 of the C5a receptor (C5aR; CD88), we demonstrate that noncysteinyl proteinases associated with vesicles obtained from P. gingivalis cleave the C5aR on human neutrophils. Proteolytic attack of the C5aR by enzymes from the P. gingivalis vesicles was inhibited by TPCK (tolylsullonyl phenylalanyl chloromethyl ketone), PMSF (phenylmethylsulfonyl fluoride), and dichloroisocoumarin, suggesting that serine proteinases are primarily responsible for this degradative activity. The purified vesicle proteinase Lys-gingipain but not Arg-gingipain also cleaved the N-terminal region of the C5aR on the human neutrophils. Lys-gingipain activity was essentially resistant to these inhibitors but was inhibited by TLCK (Nalpha-p-tosyl-L-lysine chloromethyl ketone) and iodoacetamide. A synthetic peptide that mimics the N-terminal region of C5aR (residues 9 to 29; PDYGHY DDKDTLDLNTPVDKT) was readily cleaved by chymotrypsin but not by trypsin, despite the presence of two potential trypsin (i.e., lysyl-X) cleavage sites. The specific sites of cleavage in the C5aR 9-29 peptide were determined by mass spectroscopy for both chymotrypsin and Lys-gingipain digests. This analysis demonstrated that the C5aR peptide is susceptible to cleavage at both potential Lys-gingipain sites (i.e., between residues 17 and 18 [K-D] and 28 and 29 [K-T]) and at two chymotrypsin sites (between residues 14 and 15 [Y-D] and 20 and 21 [L-D]), respectively. These studies suggest that P. gingivalis contains at least two enzymes capable of cleaving the C5aR, Lys-gingipain and a second nontryptic serine proteinase that is distinct from either Arg- or Lys-gingipain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675297      PMCID: PMC174026          DOI: 10.1128/iai.64.6.1984-1991.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Collagenolytic activity of black-pigmented Bacteroides species.

Authors:  G Sundqvist; J Carlsson; L Hänström
Journal:  J Periodontal Res       Date:  1987-07       Impact factor: 4.419

2.  Degradation of human immunoglobulins G and M and complement factors C3 and C5 by black-pigmented Bacteroides.

Authors:  G Sundqvist; J Carlsson; B Herrmann; A Tärnvik
Journal:  J Med Microbiol       Date:  1985-02       Impact factor: 2.472

3.  Association of oral Bacteroides with gingivitis and adult periodontitis.

Authors:  D White; D Mayrand
Journal:  J Periodontal Res       Date:  1981-05       Impact factor: 4.419

4.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

5.  A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique.

Authors:  A Ferrante; Y H Thong
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

6.  Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor.

Authors:  E L Morgan; J A Ember; S D Sanderson; W Scholz; R Buchner; R D Ye; T E Hugli
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

7.  Bacteriology of severe periodontitis in young adult humans.

Authors:  W E Moore; L V Holdeman; R M Smibert; D E Hash; J A Burmeister; R R Ranney
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

8.  Polymorphonuclear leukocyte accumulation in inflammatory dermal sites as measured by 51Cr-labeled cells and myeloperoxidase.

Authors:  C Lundberg; K E Arfors
Journal:  Inflammation       Date:  1983-09       Impact factor: 4.092

9.  Selected characteristics of pathogenic and nonpathogenic strains of Bacteroides gingivalis.

Authors:  D Grenier; D Mayrand
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

10.  Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments.

Authors:  R A Wetsel; W P Kolb
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  27 in total

1.  Hydrolysis of interleukin-12 by Porphyromonas gingivalis major cysteine proteinases may affect local gamma interferon accumulation and the Th1 or Th2 T-cell phenotype in periodontitis.

Authors:  P L Yun; A A Decarlo; C Collyer; N Hunter
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

2.  Selective sorting of cargo proteins into bacterial membrane vesicles.

Authors:  M Florencia Haurat; Joseph Aduse-Opoku; Minnie Rangarajan; Loredana Dorobantu; Murray R Gray; Michael A Curtis; Mario F Feldman
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

3.  Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis.

Authors:  Natalia Wegner; Robin Wait; Aneta Sroka; Sigrun Eick; Ky-Anh Nguyen; Karin Lundberg; Andrew Kinloch; Shauna Culshaw; Jan Potempa; Patrick J Venables
Journal:  Arthritis Rheum       Date:  2010-09

Review 4.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

5.  Activities of the Porphyromonas gingivalis PrtP proteinase determined by construction of prtP-deficient mutants and expression of the gene in Bacteroides species.

Authors:  G A Barkocy-Gallagher; J W Foley; M S Lantz
Journal:  J Bacteriol       Date:  1999-01       Impact factor: 3.490

6.  Modulation of neutrophil chemokine receptors by Staphylococcus aureus supernate.

Authors:  K E Veldkamp; H C Heezius; J Verhoef; J A van Strijp; K P van Kessel
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

7.  RgpA-Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model.

Authors:  N M O'Brien-Simpson; R A Paolini; E C Reynolds
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

8.  Porphyromonas gingivalis gingipain-R enhances interleukin-8 but decreases gamma interferon-inducible protein 10 production by human gingival fibroblasts in response to T-cell contact.

Authors:  M Oido-Mori; R Rezzonico; P L Wang; Y Kowashi; J M Dayer; P C Baehni; C Chizzolini
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

9.  Reduced expression of gamma interferon in serum and marked lymphoid depletion induced by Porphyromonas gingivalis increase murine morbidity and mortality due to cytomegalovirus infection.

Authors:  Jacob Stern; Ela Shai; Batia Zaks; Amal Halabi; Yael Houri-Haddad; Lior Shapira; Aaron Palmon
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 10.  Gingipains from Porphyromonas gingivalis - Complex domain structures confer diverse functions.

Authors:  N Li; C A Collyer
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.